Table 6.
Progression free survival according to stage and risk groups
| Progression-free survival | |||||
|---|---|---|---|---|---|
| Characteristic | N | Median | 1-year | 2-year | 3-year |
| Months (95% CI) | % (95% CI) | ||||
| IIIA | |||||
| Total* | 321 | 12.5 (11.3; 13.6) | 52.9 (47.7; 58.7) | 24.1 (19.8; 29.3) | 16.8 (13.0; 21.7) |
| Good | 223 | 12.9 (12; 15.2) | 55.8 (49.6; 62.7) | 27.6 (22.3; 34.3) | 19.6 (14.8; 26.0) |
| Poor | 75 | 11.4 (7.9; 13.2) | 45.3 (35.4; 58.1) | 14.2 (8.1; 25.0) | 8.3 (3.8; 18.1) |
| IIIB | |||||
| Total* | 262 | 9.9 (9.2; 10.8) | 38.5 (33.1; 44.9) | 12.8 (9.3; 17.7) | 4.3 (1.8; 9.9) |
| Good | 146 | 10.7 (9.6; 12.6) | 43.8 (36.5; 52.6) | 13.6 (9.0; 20.8) | 8.6 (4.7; 15.5) |
| Poor | 97 | 8.6 (7.8; 9.9) | 26.8 (19.3; 37.2) | 9.9 (5.4; 18.2) | 0 |
| T3N3 and T4N3** | 84 | 9.4 (7.9; 11.3) | 34.5 (25.7; 46.3) | 10.7 (5.8; 20.0) | 2.5 (0.4; 15.1) |
| IIIA+IIIB | |||||
| Total* | 583 | 11.2 (10.2; 12.2) | 46.5 (42.6; 50.7) | 19.0 (16.0; 22.6) | 11.5 (8.9; 14.9) |
| Good | 369 | 12.2 (11.0; 13.3) | 51.0 (46.2; 56.4) | 22.1 (18.2; 26.9) | 15.4 (11.9; 19.9) |
| Poor | 172 | 9.2 (8.3; 10.5) | 34.9 (28.4; 42.8) | 11.7 (7.7; 17.7) | 3.7 (1.3; 10.8) |
| HR (95% CI) | p-value | ||||
| IIIA vs IIIB | 0.71 (0.59; 0.85) | < 0.001 | |||
| IIIA Good vs IIIA Poor | 0.69 (0.52; 0.92) | 0.011 | |||
| IIIB Good vs IIIB Poor | 0.69 (0.53; 0.90) | 0.006 | |||
| IIIA vs IIIB Good | 0.80 (0.65; 0.99) | 0.037 | |||
Good = performance status 0–1 and no weight loss; Poor = performance status 2–3 and/or weight loss ≥ 10%;
* = Total is not sum of Good and Poor, as some patients had no data about weight loss;
** = Stage IIIC in Union for International Cancer Control [UICC] 8